These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16258122)

  • 1. Comprehensive review of chemotherapy in patients with metastatic breast cancer.
    Melemed AS; Mockbee C; Orlando M
    J Clin Oncol; 2005 Nov; 23(31):8139-40. PubMed ID: 16258122
    [No Abstract]   [Full Text] [Related]  

  • 2. New advances in the management of metastatic breast cancer.
    Glück S
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S12-6. PubMed ID: 16280104
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed.
    Vogl DT; Stadtmauer EA
    Bone Marrow Transplant; 2006 Jun; 37(11):985-7. PubMed ID: 16708060
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer.
    Beinart GA; Gonzalez-Angulo AM; Broglio K; Frye D; Walters R; Holmes FA; Gunale S; Booser D; Rosenthal J; Dhingra K; Young JA; Hortobagyi GN
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):61-7. PubMed ID: 17009032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
    Gligorov J; Lotz JP
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Has first-line therapy had an impact on general outcome in metastatic breast cancer?
    McArthur HL; Hudis CA
    Future Oncol; 2007 Aug; 3(4):411-8. PubMed ID: 17661716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preoperative chemotherapy in operable breast cancer. A survey of a Cochrane review].
    Petersen MB; Ejlertsen B
    Ugeskr Laeger; 2008 Sep; 170(39):3048-50. PubMed ID: 18822229
    [No Abstract]   [Full Text] [Related]  

  • 8. Treating in the dark: unanswered questions on costs and benefits of late line therapy for metastatic breast cancer.
    Anders CK; Peppercorn J
    Cancer Invest; 2009 Jan; 27(1):13-6. PubMed ID: 19160108
    [No Abstract]   [Full Text] [Related]  

  • 9. [Chemotherapy for metastatic breast cancer].
    Schmid P; Possinger K
    Zentralbl Gynakol; 2006 Dec; 128(6):318-26. PubMed ID: 17213969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending survival with chemotherapy in metastatic breast cancer.
    O'Shaughnessy J
    Oncologist; 2005; 10 Suppl 3():20-9. PubMed ID: 16368868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
    Hamberg P; Verweij J; Seynaeve C
    Eur J Cancer; 2007 Jul; 43(10):1514-28. PubMed ID: 17482454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy.
    Marsh S; Liu G
    Adv Drug Deliv Rev; 2009 May; 61(5):381-7. PubMed ID: 19100797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab: new indication. Metastatic breast cancer, in combination with docetaxel: promising, but more evaluation is needed.
    Prescrire Int; 2006 Feb; 15(81):3-5. PubMed ID: 16548094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of breast cancer.
    Moulder S; Hortobagyi GN
    Clin Pharmacol Ther; 2008 Jan; 83(1):26-36. PubMed ID: 18091763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological therapy of breast cancer: recent clinical applications.
    Baar J
    Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2 study of perifosine in advanced or metastatic breast cancer.
    Leighl NB; Dent S; Clemons M; Vandenberg TA; Tozer R; Warr DG; Crump RM; Hedley D; Pond GR; Dancey JE; Moore MJ
    Breast Cancer Res Treat; 2008 Mar; 108(1):87-92. PubMed ID: 17458693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival impact of integrative cancer care in advanced metastatic breast cancer.
    Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
    Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for early breast cancer.
    Hargis JB; Jain D
    J Ky Med Assoc; 2009 Oct; 107(10):401-6. PubMed ID: 19873798
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.
    Ellard SL; Clemons M; Gelmon KA; Norris B; Kennecke H; Chia S; Pritchard K; Eisen A; Vandenberg T; Taylor M; Sauerbrei E; Mishaeli M; Huntsman D; Walsh W; Olivo M; McIntosh L; Seymour L
    J Clin Oncol; 2009 Sep; 27(27):4536-41. PubMed ID: 19687332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.